Express Pharma

MIMS Research Foundation is developing a novel drug to treat coronavirus

The company have repurposed its sepsis research for COVID management

2 900

MIMS Research Foundation, a research arm of Aster DM Healthcare is developing a polyclonal antibody to stop cytokine storm in coronavirus. The researchers aim to prevent coronavirus related deaths with the novel drug.

Reportedly, there are no approved products available across the globe that are affordable and effective for wide clinical use against viral-induced sepsis. The severity of coronavirus is directly proportional to the concentration of cytokines released in response to the infection. Controlling cytokine storm is essential to prevent coronavirus-related deaths. So, MIMS Research Foundation is proposing to develop an antibody therapy to save millions of cases across the globe.

Dr Satish Prasad Rath, Group Chief of Innovation and Research- Aster DM Healthcare said, “We have repurposed our sepsis research for COVID management. The antibody is developed to treat bacterial sepsis by blocking the Cytokine storm. The immune response during COVID 19 infection also leads to organ dysfunction as bacterial sepsis do. Additionally, the severity of COVID is directly proportional to the concentration of cytokines released in response to the infection. Controlling cytokine storm is essential to prevent the coronavirus related deaths, hence we are proposing to use this antibody to treat COVID induced organ damage and septic shock.”

He added, “Respiratory infections are frequently associated with systemic inf